Vanda Pharmaceuticals

Vanda Pharmaceuticals

VNDA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +84.1% in FY2025

Mihael H. Polymeropoulos, M.D. is the CEO of Vanda Pharmaceuticals and was paid $3.9M in FY2025 (Dec), down 1%.

Pay$100 in the stock at the end of FY20 → $67
CEO pay is from each Vanda Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Mihael H. Polymeropoulos, M.D.FY2025
  2. 2Joakim WijkstromFY2025
  3. 3Timothy WilliamsFY2025
  4. 4Kevin MoranFY2025
  5. 5Gunther BirznieksFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Vanda Pharmaceuticals paid its 5 named executives $9.6M in total in FY2025 (Dec). CEO Mihael H. Polymeropoulos, M.D. was paid $3.9M of that.

Name
Mihael H. Polymeropoulos, M.D.President, Chief Executive Officer and Chairman of the Board
Joakim WijkstromSenior Vice President, Chief Marketing Officer
Timothy WilliamsSenior Vice President, General Counsel and Secretary
Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer
Gunther BirznieksSenior Vice President, Business Development

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Vanda Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Anne Sempowski WardDirector · 5 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
  • Phaedra S. ChrousosDirector · 5 yr on the boardIndependentAudit, Corporate Governance (Chair)—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    Vanda Pharmaceuticals CMO pay rose 37% to $1.5M. The stock rose 84% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Vanda Pharmaceuticals CMO pay fell 22% to $1.1M. The stock rose 14% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Vanda Pharmaceuticals General counsel pay fell 26% to $1.5M. The stock fell 53% in FY2022 (Dec).
    DEF 14A
  4. Pay
    Vanda Pharmaceuticals CEO pay fell 13% to $3.7M. The stock fell 43% in FY2023 (Dec).
    DEF 14A
  5. Pay
    Vanda Pharmaceuticals CEO pay fell 31% to $4.3M. The stock fell 53% in FY2022 (Dec).
    DEF 14A
  6. Pay
    Vanda Pharmaceuticals CFO pay fell 27% to $1.4M. The stock fell 53% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Vanda Pharmaceuticals CMO pay fell 16% to $1.4M. The stock fell 43% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Vanda Pharmaceuticals CMO pay fell 13% to $1.6M. The stock fell 53% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Vanda Pharmaceuticals Senior Vice President, Business Development pay fell 26% to $1.5M. The stock fell 53% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KFeb 12, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 14, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 8, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data